NasdaqCM:NURO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.


Similar Companies

Share Price & News

How has NeuroMetrix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NURO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.0%

NURO

1.5%

US Medical Equipment

1.8%

US Market


1 Year Return

-55.1%

NURO

16.2%

US Medical Equipment

14.2%

US Market

Return vs Industry: NURO underperformed the US Medical Equipment industry which returned 16.2% over the past year.

Return vs Market: NURO underperformed the US Market which returned 14.2% over the past year.


Shareholder returns

NUROIndustryMarket
7 Day-4.0%1.5%1.8%
30 Day-17.0%1.2%0.04%
90 Day-14.0%12.3%9.8%
1 Year-55.1%-55.1%17.2%16.2%16.7%14.2%
3 Year-91.8%-91.8%75.0%70.4%41.6%32.2%
5 Year-99.4%-99.4%144.8%126.4%90.9%69.5%

Price Volatility Vs. Market

How volatile is NeuroMetrix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NeuroMetrix undervalued compared to its fair value and its price relative to the market?

1.14x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NURO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NURO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NURO is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: NURO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NURO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NURO is good value based on its PB Ratio (1.1x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is NeuroMetrix forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NeuroMetrix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has NeuroMetrix performed over the past 5 years?

37.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NURO is currently unprofitable.

Growing Profit Margin: NURO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NURO is unprofitable, but has reduced losses over the past 5 years at a rate of 37.8% per year.

Accelerating Growth: Unable to compare NURO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NURO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: NURO has a negative Return on Equity (-72.34%), as it is currently unprofitable.


Next Steps

Financial Health

How is NeuroMetrix's financial position?


Financial Position Analysis

Short Term Liabilities: NURO's short term assets ($7.4M) exceed its short term liabilities ($2.4M).

Long Term Liabilities: NURO's short term assets ($7.4M) exceed its long term liabilities ($698.1K).


Debt to Equity History and Analysis

Debt Level: NURO is debt free.

Reducing Debt: NURO has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NURO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NURO has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 19.8% each year.


Next Steps

Dividend

What is NeuroMetrix current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NURO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NURO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NURO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NURO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NURO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.0yrs

Average management tenure


CEO

Shai Gozani (55 yo)

23.67yrs

Tenure

US$775,030

Compensation

Dr. Shai N. Gozani, M.D., Ph.D., founded Neurometrix Inc. in 1996 and has been its President since 2002 and Chief Executive Officer since 1997 and its Secretary July 2008. He has been the Chairman of the B ...


CEO Compensation Analysis

Compensation vs Market: Shai's total compensation ($USD775.03K) is above average for companies of similar size in the US market ($USD594.44K).

Compensation vs Earnings: Shai's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Shai Gozani
Founder23.67yrsUS$775.03k0.65%
$ 40.9k
Thomas Higgins
Senior VP11yrsUS$501.42k0.22%
$ 13.9k
Michael MacDonald
Senior VP of Commercial Operations & GM of Diagnosticsno datano datano data
Xuan Kong
Chief Data Scientist3.25yrsno datano data

11.0yrs

Average Tenure

Experienced Management: NURO's management team is seasoned and experienced (11 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Shai Gozani
Founder23.67yrsUS$775.03k0.65%
$ 40.9k
Nancy Katz
Independent Director9.75yrsUS$49.00k0.000080%
$ 5.0
David Goodman
Independent Director16.25yrsUS$47.00k0.000080%
$ 5.0
Arthur Vinik
Member of Scientific Advisory Board9.5yrsno datano data
Andrew Boulton
Member of the Scientific Advisory Board9.5yrsno datano data
David Van Avermaete
Independent Director7yrsUS$41.00k0%
$ 0
Neil Brooks
Member of the Scientific Advisory Board9.5yrsno datano data
David Armstrong
Member of the Scientific Advisory Board9.5yrsno datano data
Solomon Tesfaye
Member of the Scientific Advisory Board9.5yrsno datano data
Dan Ziegler
Member of the Scientific Advisory Board9.5yrsno datano data
Bruce Perkins
Member of the Scientific Advisory Board9.5yrsno datano data
Jiro Nakamura
Member of Scientific Advisory Board6.67yrsno datano data

9.5yrs

Average Tenure

62.5yo

Average Age

Experienced Board: NURO's board of directors are considered experienced (9.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 286.9%.


Top Shareholders

Company Information

NeuroMetrix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NeuroMetrix, Inc.
  • Ticker: NURO
  • Exchange: NasdaqCM
  • Founded: 1996
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$6.283m
  • Shares outstanding: 3.78m
  • Website: https://www.neurometrix.com

Number of Employees


Location

  • NeuroMetrix, Inc.
  • 4B Gill Street
  • Woburn
  • Massachusetts
  • 1801
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NURONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2004
NLZDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2004

Biography

NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimul ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/18 06:04
End of Day Share Price2020/09/17 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.